This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.
Storage
-20°C
References
Ref: Renno, R. et al. Invest. Ophthalmol. Vis. Sci. 43, 3977 (2002); Brekken, R. et al. Cancer Res. 60, 5117 (2000); Jia, H. et al. J. Biol. Chem. 279, 36148 (2004); Ye, F. Gynecol. Oncol. 94, 125 (2004); Bin?truy-Tournaire, R. et al. EMBO J. 19, 1525 (2000).
